Carmen Olga Torre
A5080283831- Rheumatoid Arthritis Research and Therapies
- COVID-19 and Mental Health
- Mental Health Research Topics
- Tuberculosis Research and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- COVID-19 Clinical Research Studies
- Peripheral Neuropathies and Disorders
- Healthcare Systems and Reforms
- Treatment of Major Depression
- Pharmaceutical Economics and Policy
- Systemic Lupus Erythematosus Research
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Long-Term Effects of COVID-19
- Intensive Care Unit Cognitive Disorders
- Digital Mental Health Interventions
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Drug-Induced Ocular Toxicity
- Tryptophan and brain disorders
- Cardiac Arrhythmias and Treatments
- Biosimilars and Bioanalytical Methods
- Bipolar Disorder and Treatment
University of Hong Kong
2023-2024
University of Groningen
2023-2024
Roche (Switzerland)
2024
Roche (United Kingdom)
2023-2024
Chinese University of Hong Kong
2023
IQVIA (United Kingdom)
2020-2022
IQ Solutions
2020
IQVIA (United States)
2020
Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation emergency use to treat patients COVID-19 pneumonia. We studied safety hydroxychloroquine, alone and combination azithromycin, determine risk routine care arthritis.
ABSTRACT Background Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia. We studied safety of hydroxychloroquine, alone azithromycin. Methods New user cohort studies were conducted including 16 severe adverse events (SAEs). Rheumatoid arthritis patients aged 18+ initiating hydroxychloroquine compared to those sulfasalazine followed up over 30 days. Self-controlled case series...
Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.To a large-scale comparison between all DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) routine clinical practice.Multinational population-based cohort study.Five standardized electronic health care databases, which covered 221 million people France, Germany, United Kingdom, States.Patients...
Concerns have been raised that the use of antipsychotic medication for people living with dementia might increased during COVID-19 pandemic.To examine multinational trends in drug prescribing before and pandemic.This network cohort study used electronic health records claims data from 8 databases 6 countries (France, Germany, Italy, South Korea, UK, US) individuals aged 65 years or older between January 1, 2016, November 30, 2021. Two each were included Korea US.The introduction...
Population-wide restrictions during the COVID-19 pandemic may create barriers to mental health diagnosis. This study aims examine changes in number of incident cases and incidence rates diagnoses pandemic.
Many patients with bipolar disorder (BD) are initially misdiagnosed major depressive (MDD) and treated antidepressants, whose potential iatrogenic effects widely discussed. It is unknown whether MDD a comorbidity of BD or its earlier stage, no consensus exists on individual conversion predictors, delaying BD's timely recognition treatment. We aimed to build predictive model validate it across multi-national network patient databases using the standardization afforded by Observational Medical...
Identification of rheumatoid arthritis (RA) patients at high risk adverse health outcomes remains a major challenge. We aimed to develop and validate prediction models for variety in RA initiating first-line methotrexate (MTX) monotherapy. Data from 15 claims electronic record databases across 9 countries were used. Models developed internally validated on Optum® De-identified Clinformatics® Mart Database using L1-regularized logistic regression estimate the within 3 months (leukopenia,...
Abstract Importance Drug shortages leave affected patients in a vulnerable position. Objective To describe incidence and prevalence of use for medicines with suggested at least one European country, as announced by the Medicines Agency, to characterise users these drugs including indication use, duration dosage. Design We performed descriptive cohort study from 2010 up 2024 network databases which have mapped their data Observational Medical Outcomes Partnership (OMOP) Common Data Model...
Background: Treatment guidelines recommend early initiation of csDMARDs following diagnosis rheumatoid arthritis (RA), with methotrexate (MTX) as first-line therapy. Scarce evidence exists on adherence to this guidance Objectives: To characterize csDMARD treatment during the first year an RA diagnosis. Methods: 14 real world databases (3 Primary care, 6 primary/secondary care records, 5 claims) from 9 countries were included, all mapped OMOP common data model. Patients included earliest...
Objective: We assessed the comparative risks associated with first line conventional synthetic disease modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA).Methods: Routine health data from 8 databases (5 US, 1 UK, Germany, and Spain) informed analysis. All were transformed to OMOP common model. New users of monotherapy csDMARD after an RA diagnosis aged 18 or over 2005-2019 included study. Adverse events for methotrexate (MTX), hydroxychloroquine (HCQ), sulfasalazine (SSZ),...